21st Dec 2015 11:21
LONDON (Alliance News) - Vernalis PLC said Monday that a single-dose comparative bioavailability study has been completed for CCP-07, a cough cold treatment being developed for Vernalis by Tris Pharma Inc for the US market.
Following the completion of this study it will now move to a multiple-dose comparative bioavailability study. These studies analyse the level to which a drug is absorbed.
Vernalis said that, subject to a successful outcome for these studies, it expects to file a new drug application for CCP-07 in 2016.
"We are delighted with the continued progress of CCP-07 which further demonstrates the low-development risk of our cough cold pipeline in development with Tris, and we look forward to further news flow from these programmes, over the coming months," said Chief Executive Officer Ian Garland in a statement.
Shares in Vernalis were up 1.3% at 70.15 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC